Breast cancer, treatment switch to Anastrozole after two years of Tamoxifen is beneficial


A study, published in The Lancet, demonstrated that switching treatment to the drug Anastrozole ( Arimidex ) after two years of Tamoxifen ( Nolvadex ) can improve event-free survival for postmenopausal women with early breast cancer.

For more than 20 years Tamoxifen has been the standard treatment after surgery for postmenopausal women with hormone-responsive early breast cancer.
However, research has shown that an aromatase inhibitor called Anastrozole is effective and tolerable in this group of patients compared with Tamoxifen when used as a first-line treatment. Studies have also suggested that taking Anastrozole after two years of Tamoxifen could be beneficial.

Raimund Jakesz at Vienna Medical Universit, and colleagues from the Austrian Breast and Colorectal Cancer Study Group and the German Adjuvant Breast Cancer Group combined data from two multicentre, randomised trials looking at the effect of taking Anastrozole after Tamoxifen.

In both trials postmenopausal women who had received two years of Tamoxifen treatment were randomised to receive Anastrozole ( 1618 women ) or Tamoxifen ( 1606 women ) for a further three years.

The investigators found that after two years of follow-up there was a 40% decrease in the risk of an event for women in the Anastrozole group when compared with women on Tamoxifen ( 67 events with Anastrozole vs 110 with Tamoxifen ).
The researchers defined an event as a local or distant recurrence, or cancer arising in the other breast. More patients had bone fractures on Anastrozole but there were fewer cases of blood clots than in the Tamoxifen group.

Jakesz concludes: “ Although further investigation is necessary to ascertain the ideal sequence and duration of adjuvant endocrine therapy, this combined analysis confirms that post-menopausal women who receive Tamoxifen as adjuvant therapy should be switched to Anastrozole after 2 years of treatment.”

In an accompanying comment Anthony Howell at Christie Hospital NHS Trust, Manchester, states: “ The aromatase inhibitors show superiority over Tamoxifen when used immediately after surgery ( Anastrozole, Letrozole ) or after 2–3 years of Tamoxifen ( Anastrozole, Exemestane). Letrozole and Anastrozole also show superiorly over placebo when given after 5 years of Tamoxifen. ”

Source: The lancet, 2005


XagenaMedicine_2005



Indietro

Altri articoli

Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. Researchers have assessed the...


Aromatase inhibitors carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. New University of...


Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss.A new study has...


Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss.A new study has...


Two separate meta-analyses of clinical trials that tested Tamoxifen ( Nolvadex ) against aromatase inhibitors in postmenopausal women with early...


Two separate meta-analyses of clinical trials that tested Tamoxifen ( Nolvadex ) against aromatase inhibitors in postmenopausal women with early...


A study, conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals, found that postmenopausal women with early-stage, hormone-sensitive...


Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small...


A few years ago researchers discovered that, much like breast tumors, some lung tumors also thrive on estrogen. Now researchers...


Breast tumor specialists cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the...